Previous trials showed the importance of administering radiation therapy (RT) with small doses per fraction in canine pelvic tumours to maintain acceptable toxicity levels. With increased accuracy/precision of RT, namely intensity-modulated RT (IMRT), this approach might be challenged.
| INTRODUCTION
Radiation therapy (RT) is a valuable adjunct to therapy in canine anal sac adenocarcinoma (ASAC) in cases of incomplete surgical excision or a stand-alone treatment option for inoperable disease. [1] [2] [3] [4] Over the last decades, increasing accuracy and precision of radiation therapy (RT) has led to a partial change of paradigm in terms of fractionation schedules and prior protocols could be challenged. Because of the high density of organs at risk (OAR) in the caudal abdomen/pelvic area, early and late radiation toxicity need to be strongly considered in respect to dose per fraction as well as total dose. Arthur et al and
Anderson et al described a high incidence of rectal toxicity in pelvic irradiation with definitive-intent protocols of fraction size ≥3 Gy and rectal strictures were also common findings after treatment of canine ASAC with a protocol of 15 × 3.2 Gy in combination with chemotherapy. 1, 5, 6 In addition to fraction size, the incidence and severity of toxicity also depends on the volume definition of the treatment targets. These volumes are dependent upon the accuracy and precision of treatment delivery, determined by patient immobilization and technical specifications of the treatment planning and delivery systems in different facilities. As precision and accuracy improve, it may be that larger fraction sizes can be delivered without unacceptable toxicity.
The optimal fractionation for maximum efficacy with acceptable toxicity has not yet been determined in canine ASAC.
As earlier observations were made under the premises of less conformal RT such as cobalt therapy or 2D-RT, these results and recommendations cannot be extrapolated to techniques such as conventional 3D conformal radiation therapy (3DCRT) or intensitymodulated radiation therapy (IMRT). 1, 5, 6 IMRT is commonly delivered with image-guidance (IGRT), but also IGRT-3DCRT will allow further reduction of treatment volumes as accuracy and precision can be greatly improved.
As well-curated toxicity data are lacking in veterinary medicine, new protocols and subsequent toxicities could be approximated in a trial and error approach. However, it seems sensible to rely at least in part on the large amount of toxicity data available in human medicine that was gained from radiation protocols applied to the caudal abdominal area for treatments such as prostate and genitourinary cancers. [7] [8] [9] [10] [11] Therefore, we herein assumed that similar organs such as rectum, bladder and spinal cord would react in a similar manner, taken into account the different relative volume parameters.
The aim of this study was to use theoretical mathematical toxicity risk calculations to model early and late toxicity in a newly developed RT protocol prior to its implementation into clinical practice. Theoretical probability estimates of toxicity for a new, moderately hypofractionated, definitive-intent protocol with 12 fractions, applied with IG-IMRT were made for dogs with stage 3b ASAC, the largest loco-regional extent of disease possible. We hypothesized that the intended protocol can be applied with tolerable probability of toxicity to the abdomino-pelvic OAR. As a second hypothesis it was assumed that the probability of toxicity in the respective organs increases with the tumour volume to body-weight ratio (ie, relative tumour size).
| MATERIAL AND METHODS

| Patient data and tumour characteristics
Computed tomography (CT) datasets of client-owned dogs with ASAC presented for diagnostic and/or therapeutic purposes were reviewed.
CT datasets were included into the study if the dogs had a cytologi- OAR contouring included rectum (from the anus until the start of the colon), colon (from the pelvic inlet ie, the cranial border of the pelvic symphysis until transition into the small intestines or alternatively until the most cranial CT image), small intestines, right and left kidney, spinal cord (from the start of CT dataset cranially until the caudal end of L7 caudally), urinary bladder and urethra (from the end of the urinary bladder until the tip of penis or vulva) as shown in Figure 1 . 13 All tubular structures (rectum, colon and small intestines) were contoured FIGURE 1 Transverse computed tomography image depicting the gross tumour volume (GTV, pink), clinical target volume (CTV, yellow), planning target volume (PTV, red) and the organs at risk (OAR) colon (green), spinal cord (orange) and urinary bladder (yellow). As planning aids, the following helper structures were created for this region: Colon_minPTV2mm (purple) and Body_minPTV3mm (cyan), where the organ at risk was cropped with an additional margin of 2 mm (colon) or 3 mm (body) from the PTV) [Colour figure can be viewed at wileyonlinelibrary.com] as a cylinder, that is, including wall and contents. Tumour-related volumes were defined as follows: the visible tumour as seen on coregistered contrast-enhanced CT images was delineated as gross tumour volume (GTV), the clinical target volume (CTV) accounted for microscopic disease and the planning target volume (PTV) accounted for systematic and random uncertainties. Those volumes were delineated as follows: The primary anal sac adenocarcinoma was contoured based on co-registered contrast-enhanced CT images and named "GTV_Primary," the enlarged/ metastatic lymph nodes were contoured in the same way and named "GTV_LymphNodes." The remaining, non-enlarged lymph nodes in this area (bilateral medial iliac, internal iliac and sacral lymph nodes) were contoured as "CTV_Lymph-Nodes" and combined with the "GTV_LymphNodes" to form the "CTV_LymphNodesCombined." A 10 mm GTV-CTV margin ("CTV_Primary") surrounding the primary tumour was delineated, including the entire wall of the rectum if adjacent to the primary tumour but otherwise excluding rectum and anal sphincter and cropping it on the surface of the skin. Addition of a CTV-PTV expansion margin of 5 mm to both "CTV_Primary" and "CTV_LymphNodesCom-bined" was performed ("PTV_Primary," "PTV_LymphNodes," respectively). Both "PTV_Primary" and "PTV_LymphNodes" were combined to the "PTV_combined." This margin of 5 mm has been previously determined for use with our institution's patient positioning device in the caudal abdominal area using daily image-guidance. 14,15 A 10 mm soft-tissue equivalent bolus was contoured to cover the perianal region where the PTV extended up to the surface of the body contour in order to allow dose build-up. Helper structures were segmented where needed: "Colon_minPTV2mm," "Rectum_minPTV2mm," "SpinalCord_minPTV2mm" and "Body_minPTV3mm." Those structures were contoured by first using the boolean operator tool and copying the OAR colon, rectum or spinal cord, respectively; and second, "PTV_combined" was cropped from each structure with a gap of 2 or 3 mm, respectively between PTV and the helper structure. This created a helper structure excluding the region with PTV-OAR overlap and thereby facilitating inverse treatment planning.
| Calculations of fractionation regime
In order to compute a novel, definitive-intent, moderately hypofractionated RT protocol for treatment of macroscopic ASAC with fraction dose escalation compared with the previously published (palliative approach) protocol of 8 × 3.8 Gy, equivalent dose in 2 Gy fraction (EQD 2 ) calculations were performed (Table 1) . 16, 17 An α/β ratio of As previously described for deriving risk of toxicity calculations in brain, this isoeffect computation allows for adjustment of the dose per fraction. Based on this similar anti-tumour effectiveness (TCP), the 12-fraction protocol was assessed for toxicity. As the dose per fraction is greater, the risk for toxicity could increase and needs assessment. Recommendations for specification of dose were adhered to as proposed by the International Commission on Radiation Units and Measurements (ICRU) report 83. 20 An ICRU reference point was set as a representative point in the PTV on the 100% isodose line. The dose was normalized to ensure that ≥98% of the PTV was covered by the 95% isodose line.
| Auxiliary dose-volume constraints for inverse planning
Auxiliary dose-volume constraints for IMRT-planning were derived from published recommendations for 3D-treatment planning for humans based on the QUANTEC reports. [7] [8] [9] [10] [11] 21 Based on the original fraction number, α/β ratio and dose-volume constraint (eg, V50 < 50%) from QUANTEC, the dose-volume constraints were recalculated to the same biologically effective dose (BED) for the new 12-fraction protocol according to the linear-quadratic law ( Table 2 , Supporting Information). 22 The recalculated constraints helped to prioritize minimizing dose to OAR during the treatment planning process, but first priority remained in optimal PTV coverage.
| Normal tissue complication probability computations
Normal tissue complication probability ( where Φ(x) is the probit function: Abbreviations: IMRT, intensity-modulated radiation therapy; QUANTEC, quantitative analysis of normal tissue effects in the clinic. The recalculated constraint assumptions were made using the formula BED, with alpha/beta ratio according to the organs' individual references. This served as planning aid during optimization. TD 50 is the dose that leads to a 50% complication probability for uniform whole organ irradiation and the parameter m represents the slope of the curve at TD 50 . EUD is the equivalent uniform dose representing a homogeneous dose distribution to the whole organ, which results in equal biological effect as the inhomogeneous dose distribution. The EUD is assumed to be equal to the generalized mean dose GMD. GMD is calculated from the dose-volume pairs {v i , i } of the DDVH:
Parameter sets for n, m and TD 50 used in this model were taken from Burman et al, which are based on fits to human normal tissue data (rectum, small bowel, kidney, urinary bladder and spinal cord)
compiled by Emami et al. 25, 26 Throughout the manuscript, toxicity grading is referred to Radiation Therapy Oncology Group (RTOG) criteria and summarized and compared with Veterinary Radiation Therapy Oncology Group (VRTOG) criteria in Table 3 . t test evaluated the difference of sample mean with respect to the major toxicity cut-off (set at less than 30% for early and at less than 10% for late toxicity). The non-parametric Spearman correlation (rho) was applied to disclose monotone associations between two continuous variables. Moreover, dense potential cut-offs (in increments of tens for early toxicity and in increments of fives for late toxicity) were set for early and late toxicity estimates in order to assess their tolerability in more detail. Based on cut-offs, absolute and relative frequencies were computed. Results of statistical analysis with P-values <0.05
were interpreted as statistically significant.
3 | RESULTS
| Protocol calculations
Using the EQD 2 dose calculation, a protocol with 12 × 3.8 Gy was assumed to be isoeffective (eg, equipotent) in terms of tumour control to the standard 15 × 3.2, 18 × 2.7 or 20 × 2.5 Gy protocol with an EQD 2 (α/β = 10) of 52.44 Gy and herein applied for the risk estimation (Table 1) .
| Patient, tumour and radiation dose characteristics
IMRT-treatment plans were made for 18 dogs, of which 13 were female (12 spayed) and 5 were male (all neutered). The dogs were of various pure (n = 11) and mixed breeds (n = 7) and a total of eight [32] [33] [34] [35] Also for the late toxicity, the risk correlates positively with the PTV/weight parameter (rho = 0.565; P = 0.001).
Mean and median probability of risk for late toxicities in urinary bladder, right kidney, as well as in small bowel were <1% and hence negligible. 25, 36 The toxicity to the left kidney was relevant only in one case where the risk of (unilateral) clinically relevant nephritis was estimated to be 61.3%. The mean probability of risk for spinal cord damage consisting of myelopathy calculated with an α/β ratio of 0.87 Gy was 15.0% (AE21.0), ranging from 0% to 65.5%; median of 4.4% (IQR:
24.0; 95%CI: 4.6, 25.5). 11 The risk of spinal cord myelitis/necrosis with an α/β ratio of 2 Gy was estimated for a mean of 6.4% (AE8.2), ranging from 0 to 23.6% 25 ; median of 2.9% (IQR: 9.9; 95%CI: 2.3, 10.5) 25 . Both risks were weakly depending on PTV/weight with rho = 0.333, (P = 0.015) and rho = 0.389, (P = 0.007), respectively.
| Normal tissue complication probabilitiesgraded risk
In order to achieve local tumour control, early toxicity is to be expected and tolerated to a certain amount. Herein, we used 30% of risk to develop a (transient) early toxicity as an acceptable cut-off. All early toxicity probabilities were significantly lower than 30% (P < 0.001). The same was true for an estimated accepted risk of late toxicity (lower than 10%), which was met for rectum, small bowel and bladder. For spinal cord as well as for the left kidney toxicity probabilities, the risk was higher than 10% in some patients (myelopathy P = 0.081; myelitis/ necrosis P = 0.081, unilateral nephropathy P = 0.095). 25 In order to provide an estimate of the relative (grouped) probability of complications for treating patients with the herein proposed protocol, the risks for complications for the structures at risk were graded into the following classes: early toxicity: 0% to 10%, 10%
to 20%, 20% to 30%, 30% to 40%, >40% and for late toxicity 0% to 5%, 5% to 10%, 10% to 15%, >15% (Table 4) .
| DISCUSSION
Anal sac adenocarcinomas in dogs are most commonly treated with surgery, the role of RT is currently unclear. 3, 4 However, because of the high risk of metastases, often involving multiple medial and internal iliac, as well as sacral lymph nodes, adequate locoregional control 34.96 Gy) reduced tumour volumes and relieved the severe symptoms associated with large bulky disease in the caudal abdominal region, which provides evidence of efficacy of RT in this disease entity. 16 As implicated by the sigmoid shape of the dose-response-curve, a longer tumour control can be expected with a higher dose of radiation and this justifies applying a definitive-intent protocol to treat this disease presenting in a loco-regionally advanced stage.
As often the case in veterinary radiation oncology, adequate CTV and PTV margins are poorly defined for most tumour types and treatment set-ups. While CTV is a margin added to the GTV to account for the extent of local (microscopic) invasion, PTV represents the random and systematic uncertainties mainly inherent to the institution's geometrical uncertainties in set-up variation and the patient's organ motion. 37, 38 If inadequately small margins are chosen, the risk of geographical miss with subsequent underdosage of target volumes and loss of TCP is increased and needs to be considered. [39] [40] [41] The practice of excluding (cropping) critical structures overlapping with the PTV should be discouraged to avoid underdosage of GTV and CTV. [37] [38] [39] In order to achieve similar TCP compared with previous definitive-intent protocols, an α/β ratio of 10 Gy for tumour was assumed as generally suggested. 7, 17 in vitro evaluation of α/β ratio in dog transitional cell carcinoma and osteosarcoma cell lines found rather low values suggesting that more hypofractionated protocols might have a bigger anti-tumour effect compared with finely fractionated schedules. 42, 43 Those experiments need to be valued with caution, as in vitro data is based on tumour cell data only and omits, for example, the effect of the microenvironment. The-in vitro or in vivo-α/β ratio of ASAC in dogs is not known, the authors therefore chose the generic 10 Gy value. It is important to mention, that some veterinary radiation oncologists believe that canine ASAC might also have a rather low α/β ratio but scientific evidence is currently lacking.
High incidences of late rectal toxicities were found in prior studies using definitive-intent protocols for the irradiation of caudal abdominal and pelvic neoplasia in dogs. These patients developed chronic colitis in 8% (4/51) and 56% (9/16; severe in 56% [5/9] of the latter), chronic tenesmus and narrow stool in 27%, chronic diarrhoea in 27%, intestinal stricture in 4 to 13% and intestinal perforation in 2 to 19%. 1, 5, 6 In consequence, a recommendation was made to not exceed fraction sizes of 3 Gy. However, the patients treated in these former studies were either irradiated with less optimal technology (cobalt machines) and/or-where specified-in parallel-opposed field set-ups. 1, 5, 6 Additionally, side effects in the above mentioned studies might also have been aggravated by administration of concurrent chemotherapy/radiation potentiators. 1, 5, 6 With the use of out-of-date technology, parallel-opposed fields and/or verification of position described to be provided by occasional portal images, it must be assumed that the irradiated fields were voluminous and the amount of normal tissues/OAR irradiated with high, potentially toxicity-inducing doses was large. Optimal sparing of OAR in the pelvic and caudal abdominal area is important, and fraction size alone (as prior recommended) is not the only factor contributing to dose-limiting toxicity:
also the irradiated volume contributes to the amount of toxicity. 5, 6 Daily image-guided IMRT leads to increased precision and accuracy, (PTV/weight parameter). 30, 31, 48 This risk of early rectal toxicity should be addressed when discussing treatment with the pet owner. Apart from the early toxicity occurring with a rather fixed risk estimate, late toxicity risk probability in small bowel as well as the urinary bladder is considered very low with <4% and <0.1% in each patient, respectively.
Only in one case, a high dose to the left kidney could not be avoided and risk probability for this patient was 61.3%. Two dogs had a high risk probability of 11.5% and 21.1%, respectively, for late rectal toxicity using the endpoint/calculation parameters of Cheung et al. 34 However, with endpoint/calculation parameters of another study, risk probability was low with 0.26% and 0.17% for each patient, respectively. 35 Both of these patients were very small dogs, with a consequently large relative (to body size) tumour volume. According to a more recent study by Michalski et al 7 , grade ≥2 rectal toxicity or bleeding can be avoided in human patients irradiated in the pelvic area, if V 50 < 50%, V 60 < 35%, V 65 < 25% and V 70 < 20%. In the present study, we were not able to meet the correspondingly calculated auxiliary constraints of V 50 < 50% (*V 35.8 < 50%) and V 60 < 35% (*V 41.9 < 35%) in the treatment plans for the majority of the dogs.
The V 65 < 25% (*V 45.0 < 25%) and V 70 < 20% (*V 48.0 < 20%) for rectum could be met in all dogs. Nevertheless, the doses extracted from the plans and used for NTCP calculations predicted a probability of risk for grade ≥2 rectal toxicity in 3.5% only. Of note in the proposed setting were possible late toxicities such as myelopathy in the spinal cord and require attention when bringing this protocol into clinical use. As shown in Table 4 This work presents a theoretical approach to estimate early and late radiation toxicity for a treatment protocol and the true incidence ments. This trend is also visible in human medicine, and also allocation-of-resources driven, for example, the use of fewer fractions will allow an institution to treat more patients on the available treatment machines and less fractions will also put less stress on the health care insurances.
In conclusion, the NTCP calculations for the new protocol with 12 × 3.8 Gy predict this protocol to be tolerable for most cases, even in advanced disease. The true incidence of early and late radiation toxicity will now be validated in a prospective clinical trial. In order to be able to describe and compare outcome of such a new protocol, strict adherence to correct patient positioning and target localization with image-guidance, uniform delineation of OAR and target volumes will be implemented and prescribed dose coverage will be strictly adhered to. Continued regular follow-up of patients treated with new protocols is mandatory in order to gain further insights of tissue tolerance and tumour control in dogs with ASAC in the future.
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